CClinicalTrials.gg
CompletedNCT05898880Updated Oct 2, 2026

The Effect of Acupressure on Pain, Nausea-Vomiting, and Mental Well-Being in Oncology Patients

An interventional study of Self-acupressure and Acupressure by therapists in Pain, Nausea With Vomiting Chemotherapy-Induced and Mental Health Wellness 1, sponsored by Mersin University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Mersin University · Not applicable, Interventional, and Other

Updated Oct 2, 2026Now CompletedFirst site in Turkey (Türkiye)+4 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare the effect of self acupressure and acupressure applied by therapists on pain, nausea-vomiting, and mental well-being in oncology patients.

For this purpose, 96 individuals with stage 1-stage 3 cancer will be included in the study.

The main questions it aims to answer are:

  • Is acupressure effective on pain, nausea-vomiting and mental well-being in oncology patients? Is there a difference in the effectiveness of self-acupressure and acupressure applied by therapist on pain, nausea-vomiting and mental well-being? The participants will be included in the study as three groups, namely the self-acupressure group, the acupressure group applied by the therapist, and the control group.

Self-acupressure participants will self-administer acupressure. In the acupressure group, which will be applied by the therapist, acupressure will be applied to the participants by researchers who have acupressure certificate.

In the control group, acupressure etc. No additional application will be made. Visual analog scale, nausea-vomiting and retching index, and mental well-being scales will be applied to all groups at the beginning of the study and three days after the study.

Read the detailed description

Large Intestine Meridian 4th point (Hegu/LI4), Pericardium Meridian/Neiguan (P6) point and Yintang (EX-HN 3) point will be used for acupressure application in the research.

02

Conditions studied

  • Pain
  • Nausea With Vomiting Chemotherapy-Induced
  • Mental Health Wellness 1

Keywords

  • Chemotherapy
  • Pain
  • Nausea-vomiting
  • Mental Well-Being
  • Acupressure
03

In context

Pain

2,226 studies on the registry are indexed under Pain; 917 are open to participants now.

This study's enrollment of 96 is above the median of 70 across 1,911 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Mersin University is the lead sponsor of 173 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • ≥18 years
  • Cancer patients without distant metastases in stage-1, stage-2 and stage-3 who have received at least one course of chemotherapy
  • Pain degree 4 and above (will be evaluated with a visual analog scale)
  • Nausea-vomiting degree of 4 and above (will be evaluated with a visual analog scale)
  • Receiving standard antiemetic and standard analgesic treatment (All patients included in the study should receive similar treatment.)
  • No previous acupressure experience
  • Absence of any wound or lesion in the area where acupressure will be applied.
  • Not using a different complementary approach during the collection of research data
  • Those who signed the Informed Consent Form/Written Consent Form
  • Patients without any psychiatric diagnosis will be included in the study.

Exclusion criteria

Exclusion Criteria:

  • \< 18 years old
  • Those who have not received chemotherapy before
  • Pain grade below 4 (will be evaluated with a visual analog scale)
  • Nausea-vomiting degree below 4 (will be evaluated with a visual analog scale)
  • Receiving different antiemetic and analgesic treatments
  • Previous acupressure experience
  • Any wound or lesion in the area where acupressure will be applied
  • Using a complementary approach other than acupressure at the time research data was collected
  • Those who did not sign the Informed Consent Form/Written Consent Form
  • Patients with any psychiatric diagnosis will not be included in the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
96 participants (actual)

Study arms

  • Experimental
    Self acupressure group

    The first acupressure application will be administered and taught individually by the researcher to the oncology patients in the self-administered group. Afterwards, each patient who learns the application will be asked to apply acupressure on his own for three days. In the self-acupressure group, a questionnaire form consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied first (pre-test) before the acupressure application is taught to the group by the researchers. Afterwards, patients will apply acupressure on their own for three days, and at the end of this period (post-test), a questionnaire consisting of personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. Acupressure will be applied the large intestine meridian 4th Point (LI4), the pericardium meridian Neiguan (P6) and Yintang (EX-HN3).

    Other: Self-acupressure

  • Other
    Acupressure by therapist

    In this group, acupressure will be administered to stage I, stage II, and stage III cancer patients receiving at least one course of chemotherapy for a total of three days by researchers with acupressure certification. Before the application (pre-test) by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied to the patients in the group in question. At the end of the three-day acupressure application (post-test) applied to the patients included in the study by the therapist, a questionnaire consisting of a personal information form, visual analog scale, nausea, vomiting and retching index and mental well-being scale will be applied. In the acupressure group applied by the therapist, a total of three points will be applied to the upper extremity: the 4th point of the large intestine meridian (LI4), the Pericardium Meridian/Neiguan (P6), Yintang (EX-HN3) point.

    Other: Acupressure by therapists

  • Other
    Control group

    The control group will receive the routine treatment applied in the hospital, and acupressure will not be applied to this group.

    Other: Control group

Interventions

  • OtherSelf-acupressure

    In the self-acupressure group, before the application, the tissue sensitivity will be reduced by heating and rubbing for 20 seconds without direct pressure on the acupressure points, and the points will be made ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point. Afterwards, acupressure will be applied to themselves by participants

  • OtherAcupressure by therapists

    In the acupressure group applied by therapist, before the application, the tissue sensitivity will be reduced by heating and rubbing for about 20 seconds without direct pressure on the acupressure points, and the points will be ready for acupressure application. Afterwards, sequential (breathing rhythm) compressions will be applied to the determined acupressure points by the researcher for a total of two minutes for each point without raising the finger, taking into account the pain threshold of the individual who is applied with the thumb, with 10 seconds of pressure for two seconds of relief. Two of the three different points (LI4 and P6) selected for the application will be applied symmetrically on the other extremity. Therefore, the session duration of each patient will be approximately 12 minutes, depending on the preparation and compression time on each point.

  • OtherControl group

    No intervention will be made in the control group.

06

What researchers measure

Primary outcomes

  1. Pain intensity will be evaluated with a visual analog scale.

    The patient evaluates their own pain using a scale ranging from 1 to 10, with 1 = very mild discomfort and 10 = the most severe pain the patient can imagine. Ranges for pain intensity; \<3 mild pain, 3-6 moderate pain, \>6 severe pain.

    Time frame: Change from baseline pain level at 3 days

  2. Nausea-vomiting severity will be evaluated with the Rhodes Nausea-Vomiting and Retching Index.

    Each response is scored as 0 = least distress, 4 = most distress. The patient's experience of nausea and vomiting in each of the 8 items is summed up. The highest possible value is 32, indicating the most severe symptom occurrence score.

    Time frame: Change from baseline nausea-vomiting level at 3 days

  3. Mental well-being will be evaluated using the Warwick-Edinburgh Mental Well-Being Scale.

    The scale is in the 5-point Likert type and a minimum of 14 and a maximum of 70 points are obtained from the scale. Scoring of the scale is (1 = strongly disagree, 2 = disagree, 3 = somewhat agree, 4 = agree, 5 = completely agree).

    Time frame: Change from baseline mental well-being level at 3 days

07

Study locations

1 site
  • Mersin University Faculty of Nursing
    Mersin, Yenişehir, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Status
Not yet recruiting→Completed
changed Oct 2, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Mersin University Faculty of Nursing · Mersin, Turkey (Türkiye)
Oct 2, 2026
Primary completion
Jul 31, 2023→Jun 5, 2023 (actual)
Oct 2, 2026
Study completion
Aug 24, 2023→Sep 30, 2023 (actual)
Oct 2, 2026
Enrollment
93 (estimated)→96 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Not yet recruiting→Completed
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Mersin University Faculty of Nursing · Mersin, Turkey (Türkiye)
    Primary completion Jul 31, 2023→Jun 5, 2023 (now actual)
    Study completion Aug 24, 2023→Sep 30, 2023 (now actual)
    Enrollment 93 (estimated)→96 (actual)
    + 4 other changes: verification date, description, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05898880
Lead sponsor
Mersin University
Responsible party
Esra Cavusoglu (Principal Investigator, Mersin University) — Principal investigator
First posted
Jun 12, 2023
Start date
Jun 5, 2023
Primary completion
Jun 5, 2023
Completion
Sep 30, 2023
Last update
Oct 2, 2026

Study contacts

Esra Çavuşoğlu, Doctorate
study director · Mersin University
Hilal Altundal Duru, Doctorate
principal investigator · Çankırı Karatekin University
Kadir Eser
principal investigator · Mersin University
Emel Sezer
principal investigator · Mersin University
Vehbi Erçolak
principal investigator · Mersin University
Ümmügülsüm Kılıç
principal investigator · Mersin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion